Navigation Links
Data from Multiple Clinical Trials of OrbusNeich's Genous™ Bio-engineered R Stent™ Demonstrate Safety and Effectiveness Across Challenging Patient Subsets as Presented at TCT 2010
Date:9/25/2010

nduces less neointimal hyperplasia than bare metal stents," said Professor Wojakowski.  "These data confirm that Genous is safe and effective in patients with ACS with no stent thrombosis."

Genous Bio-engineered R stent shows complete endothelialization in majority of patients at 30 days post-implantation.

Dr. Pasi Karjalainen, M.D., Ph.D., of the Satakunta Central Hospital in Pori, Finland, presented 30-day follow-up optical coherence tomography (OCT) evaluations from 13 patients treated with the Genous Bio-engineered Cobalt Chromium Stent. The findings showed:

  • Out of 2224 stent struts, 96 percent analyzed were completely covered at 30 days.

  • The Doppler assessment of coronary flow velocity (CFR) demonstrated a functional endothelium at 30 days in almost all patients.

Dr. Karjalainen commented, "The complete endothelialization at 30 days in patients treated with the Genous stent demonstrates the ability of the EPC capture technology to accelerate the body's natural healing process."

Al Novak, Chairman and CEO of OrbusNeich, added, "The extensive clinical data sets presented today further support the use of the Genous Bio-engineered R stent as a safe and effective treatment option in challenging cases."

The symposium, which was chaired by Professor Dr. Sigmund Silber, M.D., Ph.D., of the Kardiologische Klinik Dr Muller, Munich, also featured a presentation about OrbusNeich's next generation Combo™ Bio-engineered Sirolimus Eluting Stent (Combo Stent). Professor Michael Haude, M.D., of Medical Clinic I at the Lukaskrankenhaus in Neuss, Germany, presented "The Future in DES: Combo."

About Genous  

Genous is OrbusNeich's patented endothelial progenitor cell (EPC) capture technology that promotes the accelerated natural healing of the vessel wall after the implantation of blood-contact devi
'/>"/>

SOURCE OrbusNeich
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
2. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
3. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
4. Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma
5. Multiple NIH Phase 2 HIV Vaccine Trials Using Vicals Technology Produce Encouraging Results
6. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
7. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
8. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
9. Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
10. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
11. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... and LONDON , August 28, ... approach seamlessly connects people, ... improving outcomes and the cost ... PHG AEX: PHIA) today announced its presence at  ESC ... cardiology solutions, including Heart Model A.I. , EchoNavigator and IntelliSpace ...
(Date:8/27/2015)... CUPERTINO, Calif. , Aug. 27, 2015 ... management is scheduled to present at three upcoming healthcare ... , President and CEO, will present at the Rodman ... 10:00 a.m. Eastern time. The conference is being held ... York City . A live audio webcast of ...
(Date:8/27/2015)... Aug. 27, 2015  Eli Lilly and Company (NYSE: ... Healthcare Conference on Thursday, September 17, 2015. Sue ... Lilly Oncology and Richard Gaynor , M.D., senior ... Lilly Oncology, will participate in a fireside chat at ... live audio webcast will be available on the "Webcasts ...
Breaking Medicine Technology:Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 2Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 3Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 4DURECT to Participate in Upcoming Healthcare Conferences 2Lilly to Participate in Morgan Stanley Global Healthcare Conference 2
... Parkinson,s Disease, ... Decision Resources, WALTHAM, Mass., Aug. 13 Decision ... focusing on pharmaceutical and,healthcare issues, finds that 61 percent ... drug treatment in the first year of,diagnosis. According to ...
... VIENNA, Va., Aug. 14 CEL-SCI CORPORATION,(Amex: ... an agreement with a,biomedical real estate group under which ... for its cancer drug Multikine(R). The,financial value of this ... located near Baltimore, Maryland. Once fully built out to ...
Cached Medicine Technology:Sixty-One Percent of Newly Diagnosed Parkinson's Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis 2Sixty-One Percent of Newly Diagnosed Parkinson's Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis 3CEL-SCI Secures Manufacturing Facility for Multikine Cancer Drug 2CEL-SCI Secures Manufacturing Facility for Multikine Cancer Drug 3CEL-SCI Secures Manufacturing Facility for Multikine Cancer Drug 4
(Date:8/30/2015)... ... August 31, 2015 , ... Avid collector Andrew Hawley ... Doors Shrine Auditorium concert posters. This hand colored artwork is one of the most ... Los Angles. Hawley states, "When the doors played the Shrine, the band was ...
(Date:8/30/2015)... ... August 31, 2015 , ... ChopChop Kids, the nonprofit publisher ... recently elected two new officers to serve on the organization’s Board of Directors ... and teaching kids to cook real food with their families and help continue ...
(Date:8/30/2015)... ... August 30, 2015 , ... Scientists in France say asbestos exposure ... of digestive cancers. Surviving Mesothelioma has just posted an article on the new research. ... Caen measured the cancer incidence among 2,024 French asbestos plant workers from 1978 to ...
(Date:8/30/2015)... ... August 30, 2015 , ... Nutritional Products International ( ... to Executive Assistant to CEO Mitch Gould for Nutritional Products International. Through ... goals. Kathleen graduated from Florida State University with a Bachelor of Science ...
(Date:8/29/2015)... ... August 29, 2015 , ... On Saturday, September 19, 2015, Diane ... Foundation (Meso Foundation) will present an educational program titled “Asbestos and Your Health.” ... through 9:30 PM (doors open at 6:45pm) at Calvary United Methodist Church, 16 E ...
Breaking Medicine News(10 mins):Health News:ChopChop Kids Appoints New Chair and Vice-Chair to Board of Directors 2Health News:ChopChop Kids Appoints New Chair and Vice-Chair to Board of Directors 3Health News:Researchers Say Mesothelioma Not the Only Cancer Linked with Asbestos Exposure, According to Surviving Mesothelioma 2Health News:NPI Appoints New Executive Assistant To CEO 2Health News:Mesothelioma Applied Research Foundation to Hold Educational Class About Asbestos and Mesothelioma Prevention 2
... likely woman was first infected with dangerous germ, , , WEDNESDAY, ... their food and more with their pets, but one thing ... is a drug-resistant staph infection. , However, according to a ... England Journal of Medicine , a German family appears to ...
... Public Understanding of a,21st Century Epidemic, ... of the,population, experts warn that Alzheimer,s disease ... and unsustainable burdens in,terms of health care ... lost to a devastating disease., (Photo: ...
... 2008, LANCASTER, Pa., March 12 Herley Industries,Inc. ... the second quarter,ended February 3, 2008., Net sales ... $34.7 million. Net loss for the period was approximately ... Company,s Chairman and CEO, will host a conference call,on ...
... 3 and Turmeric ... Supplement, LEXINGTON, ... the latest addition to their family of joint,relief products, which can be ... formula containing Omega 3 and,Turmeric for double strength joint relief., Over ...
... Caregivers were stressed, ate poorly, study found , , WEDNESDAY, March ... serious heart problem may raise your own risk of cardiac ... than 500 family members and others caring for a heart ... of the time were more likely to show psychological strain ...
... novel aerosol version of the most common tuberculosis ... an oral mist, offers significantly better protection against ... dose of the traditional injected vaccine, researchers report ... Academy of Sciences. , The aerosol vaccine -- ...
Cached Medicine News:Health News:Woman and Cat Shared 'Super Bug' 2Health News:Woman and Cat Shared 'Super Bug' 3Health News:New Tools Boost Alzheimer's Awareness 2Health News:New Tools Boost Alzheimer's Awareness 3Health News:Herley Reports Second Quarter Results 2Health News:Herley Reports Second Quarter Results 3Health News:Herley Reports Second Quarter Results 4Health News:Herley Reports Second Quarter Results 5Health News:Herley Reports Second Quarter Results 6Health News:Herley Reports Second Quarter Results 7Health News:Herley Reports Second Quarter Results 8Health News:Herley Reports Second Quarter Results 9Health News:Herley Reports Second Quarter Results 10Health News:The Makers of Conquer HA(TM) Launch All-Natural Double Strength Anti- Inflammatory Formula 2Health News:Caring for Heart Patients Can Strain Hearts 2Health News:Caring for Heart Patients Can Strain Hearts 3Health News:Inhaled tuberculosis vaccine more effective than traditional shot 2
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
... a monopolar cautery connector extending from the ... used for electrosurgery when properly attached to ... ,Ethicon Endo-Surgery provides disposable handheld instruments ... Our handheld instruments come in 5mm and ...
... The Featured Products ... at Mediflex and are ... modular in regular or ... come equipped with insulation, ...
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
Medicine Products: